Live Investor Briefing – Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)

Live Investor Briefing

Register for an Upcoming Webcast

Please join us for a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke.

In the session, Steven will discuss:

  • An introduction into the amazing field of CAR-T, and how Prescient’s next gen CAR-T platform, OmniCAR, is seeking to take this burgeoning cancer field to the next level.
  • Our encouraging progress through clinical trials of Prescient’s foundational assets PTX-100 and PTX-200.

This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.

Book Your Spot

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.

FEATURE SPEAKER

Steven Yatomi-Clarke (Speak feature)

Steven Yatomi Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.